An interventional study of AIa assisted diagnosis in Peri-implant Mucositis, sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Mucositis with a site in China — 5 open to participants now, 5 under way, none of them phase 3. Mucositis · China.
Among the 10 studies in Mucositis with a site in China, this one is the only one that started in 2025, is one of 3 with no phase, and was the 8th registered.
265 studies on the registry are indexed under Mucositis; 34 are open to participants now.
Browse Mucositis studies →5 of the 10 studies in Mucositis with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18–65
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Sites in China
Ages 18–75
The General Hospital of Western Theater Command · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 15–65 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 21 Mucositis studies recruiting now, 13 (62%) set no upper age limit and 7 (33%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 45 across 215 interventional studies indexed under Mucositis.
Median enrollment 99 across the 8 interventional studies, 360 across the 2 observational. Of the 1 that completed or were terminated, 1 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 8 most frequent:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University is the lead sponsor of 165 studies on the registry; 73 are open to participants now.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University has 1 study filed under Mucositis — fewer than ten, so there is no comparison to draw.
1 of the studies in Mucositis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400328The First Affiliated Hospital of Soochow UniversityAmimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Mucositis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objectives
This diagnostic study aims to:
Develop and validate a core colorimetric index that objectively quantifies mucosal erythema from digital intraoral scan data.
Develop and validate an AI model that automatically calculates this index and provides a binary diagnosis (erythema present/absent) at the image level.
Develop and validate a second AI model for precise localization (object detection) of erythematous regions on standard clinical software screenshots.
Evaluate the clinical utility of the AI system by assessing its impact on the diagnostic accuracy, consistency, and confidence of clinicians with varying experience levels.
Study Design
This is a multiphase diagnostic accuracy study conducted at a single academic center. It comprises three sequential phases with independent validation:
Phase 1 (Development \& Internal Validation): Analysis of intraoral scans to derive the color index and train the AI models using an internal dataset.
Phase 2 (External Technical Validation): Prospective validation of the trained AI models on an independent cohort of patients from a separate branch of the hospital.
Phase 3 (Clinical Utility Assessment): A prospective, controlled, observer study where clinicians perform diagnoses with and without AI assistance.
Participants and Methods
Data Source: Adult patients with dental implants who received intraoral scans using a 3Shape TRIOS 3 scanner.
Image Data: Two formats are used: 1) Processed 3D surface files (PLY format) for colorimetric analysis, and 2) Standardized 2D screenshots from the 3Shape software for object detection.
Reference Standards: Expert consensus on erythema (primary) and Bleeding on Probing (BOP, clinical inflammatory standard).
AI Development: Deep learning models (e.g., convolutional neural networks) will be trained for index calculation, image-level diagnosis, and region localization.
Observer Study: Participating clinicians (experts, general dentists, and students) will diagnose a set of test images both unaided and with AI assistance (which displays the color index value and/or bounding boxes).
Key Outcome Measures
Diagnostic Accuracy: Area under the receiver operating characteristic curve (AUC), sensitivity, specificity (with 95% confidence intervals).
Technical Performance: Intraclass correlation coefficient (ICC) for automated measurement agreement; Mean Average Precision (mAP) and Dice Similarity Coefficient for object detection.
Clinical Impact: Change in diagnostic accuracy (AUC), inter-observer agreement (Kappa), and diagnostic confidence scores when using AI assistance.
Consecutive patients aged 18 and above, with single or splinted implant-supported restorations visiting the Department of Oral and Maxillofacial Implantology Shanghai Ninth People's Hospital for regular implant maintenance will be included. Participants were excluded if i) pregnancy or intention to become pregnant; ii) with any systemic diseases/conditions that are to dental implant treatment; and iii) inability or unwillingness to give written .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this single-arm study undergo evaluation using the investigational AI-based colorimetric system. The study involves two distinct participant roles: 1) Patient Participants who have previously received intraoral scans contribute their de-identified digital dental images (3D surface files and 2D screenshots) for AI model development and validation. 2) Clinician Participants (including experts, general dentists, and students) take part in a prospective observer study. In a controlled, crossover manner, they diagnose a standardized set of peri-implant mucosal images first without any aid, and then with the assistance of the AI system, which provides an objective color index value and visual bounding boxes around suspected erythematous regions. The primary aim for this arm is to assess the diagnostic accuracy, reliability, and clinical utility of the AI system across both technical (vs. expert reference) and human (clinician performance enhancement) endpoints.
Diagnostic Test: AIa assisted diagnosis
Participants in this single-arm study undergo evaluation using the investigational AI-based colorimetric system. The study involves two distinct participant roles: 1) Patient Participants who have previously received intraoral scans contribute their de-identified digital dental images (3D surface files and 2D screenshots) for AI model development and validation. 2) Clinician Participants (including experts, general dentists, and students) take part in a prospective observer study. In a controlled, crossover manner, they diagnose a standardized set of peri-implant mucosal images first without any aid, and then with the assistance of the AI system, which provides an objective color index value and visual bounding boxes around suspected erythematous regions. The primary aim for this arm is to assess the diagnostic accuracy, reliability, and clinical utility of the AI system across both technical (vs. expert reference) and human (clinician performance enhancement) endpoints.
Diagnostic accuracy of the AI system for detecting peri-implant mucosal erythema, as measured by the Area Under the Receiver Operating Characteristic Curve (AUC).
The primary outcome is the diagnostic accuracy of the AI-based colorimetric system in classifying an image as showing erythema or not. Accuracy is quantified by the Area Under the Receiver Operating Characteristic Curve (AUC), with expert visual diagnosis serving as the reference standard. The AUC, along with its 95% confidence interval, will be calculated separately for the internal development set and the independent external validation set to assess model performance and generalizability.
Time frame: At the completion of image analysis for the external validation set, approximately 3 months after study start
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jan 2026, 4 months after the start.
Of 67 non-industry interventional studies with no phase under Mucositis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 26. This study's planned 4 months is below that.
Counting every sponsor, half of 70 studies reached it within 12 months; a quarter within 6 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University →